Category: Articles

CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th. Management will host a fireside chat on Tuesday, September 13th at 11:45 a.m. Eastern Time.

 

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. An archive of the webcast will be available for replay following the conference for approximately 30 days.

 

About Organogenesis Holdings Inc.

 

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

The regenerative biotechnology is reducing healing times to as little as three weeks in Mohs-related surgical wounds

 

PHOENIX–(BUSINESS WIRE)–Dermistat™, one of the latest wound healing innovations by BioLab Sciences, a regenerative biotechnology company, has emerged as the go-to wound healing option for dermatologists throughout the country. Introduced earlier this year, Dermistat™ is a revolutionary regenerative therapy that is transforming the wound care industry by decreasing healing time significantly compared to the standard of care secondary closure.

 

Part of the MyOwn Skin™ suite of products, Dermistat™ uses a small sample of the patient’s healthy skin to create a gel-like substance that can create an autologous skin graft in as little as 48 hours. Used for acute surgical wounds, including Mohs procedures unable to be closed with standard plastic surgery techniques, and non-healing wounds, Dermistat™ is non-invasive, improves recovery time, is relatively painless, and creates only a small, superficial donor site wound.

 

“Dermistat™ was originally developed to treat severe burns, trauma and plastic procedures, however, BioLab Sciences modified the process enabling it to be effectively leveraged in the dermatologist’s office, allowing patients to recover faster and more completely,” said Jaime Leija, Chief Commercialization Officer at BioLab Sciences. “Dermistat™ is proving to be a valuable resource for Mohs patients as it eliminates the need to perform a graft to cover larger wounds and it significantly reduces the healing time.”

 

This novel biotechnology is based on the MyOwn Skin™ technology, which leverages a very small sample of a patient’s own skin through a non-surgical procedure to reproduce the gel-like substance within 48 hours. In many cases, Dermistat™ accelerates the healing of post-surgical and chronic wounds and because of its favorable outcomes, it is on track to disrupt the wound care industry.

 

“We have been using Dermistat™ on surgical defects post-Mohs surgery after excising skin cancer,” said Travis Gilbert, PA-C with Desert Dermatology & Skin Cancer Specialists. “The wounds were typically open for 5-7 days prior to applying Dermistat™. Prior to using Dermistat™, we would close with flaps mostly. Occasionally, we would use skin grafts. Today we are using mostly Dermistat™ to cover these acute surgical wounds. They are healing much more rapidly than secondary closure and do not require significant plastics closure.”

 

About BioLab Sciences

 

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. The company is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. Learn more at www.biolabsciences.net/.

 

Contacts
Beth Cochran, Wired PR
beth@wiredprgroup.com
(602) 758-0750

BEVERLY HILLS, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Miracle Dressing Wound Care System 21-Day Stay-in-Place Dressing has been named Wound Care Product of the Week by WoundSource, “the world’s definitive source for wound care and product information.”

 

Miracle Dressing™ Wound Care System is the only 21-day stay-in-place dressing. Wound prevention, monitoring, cleaning and topical applications can all be completed without dressing removal. This saves nursing time and reduces patient distress from frequent dressing changes.

 

The system includes Natural Marine Extract™, the ingredients of which are known to promote faster healing of the skin and better wound healing results.

 

The Wound Healing Society spotlighted the importance of dressings that can stay in place for an extended time, especially due to extended stays caused by COVID mitigation. They recommend utilizing dressings that decrease the intensity of wound care by avoiding the use of dressings that must be changed daily. This would allow over-stressed health care staff to reach more patients in an adequate time frame.

 

The Miracle Dressing System can be used for:

 

• Preventive care for pressure injuries (bed sores)
• Stage 1 and Stage 2 pressure injuries
• Skin tears and cuts
• Avulsions and abrasions
• Replacing external sutures after deep tissue closure (cesarean, plastic, superficial MOHS and excision cancer, orthopedic, cosmetic) and post-op
• First, Second and Superficial Third Degree burns
• Bruises and preventive care to stop new bruises in atrophic vulnerable skin
• Prosthetic pressure injury prevention and wound healing
• All bullous diseases, especially Epidermolysis bullosa (EB), pemphigoid, pemphigus
• About Marine Biology & Environmental Technologies (MBET) and MBET Health

 

MBET is recognized for their skin revitalization and wound care products as well as kelp reforestation and other international environmental projects.

 

MBET Health is a solutions-oriented technology company focused on solving one of the most important and intransient problems facing the world of medicine: preventing and healing wounds.

 

MBET Health was founded by Dr. Eric Lewis, a practicing dermatologist, surgeon and scientific researcher based in Beverly Hills, CA. The MBET Health management team includes medical and surgical doctors from a multitude of disciplines, pharmacists and marine biologists.

 

Beginning in 2001, their founders researched a multitude of marine compounds reported to have human health benefits. As a result of their extensive studies and tests, several compounds and systems specifically designed for rejuvenation and effective repair of damaged skin have been patented (or patent-pending). The mechanisms of action of their system’s ingredients are designed to heal intractable wounds and strengthen weak, vulnerable skin to minimize the probability of breakdown.

 

The MBET Health website provides a destination for all wound care providers, nursing staff and senior management to see for themselves the convincing before and after photos and to learn details about proper product application and dressing maintenance.

 

Contact

 

Linda Sherman Gordon
MBET Health Chief Marketing Officer
310-243-6305
Email contact
MBET Health LinkedIn
Before / After press photos available upon request

This article was originally published here

LARGO, Fla.–(BUSINESS WIRE)–BioDerm, Inc., a leading provider of disposable medical devices and wound care supplies, announced the addition of two executives to strengthen its leadership position in providing premium solutions for patients with chronic medical conditions. BioDerm President & CEO Gaet Tyranski said, “I’m ecstatic to add seasoned talent in the areas of sales and marketing and compliance to take us to the next level.”

 

Colleen Kennedy is joining BioDerm as Vice President of D2C Sales and Marketing, bringing more than 20 years’ experience driving D2C marketing programs. Most recently, Colleen directed agency teams at Bluewater Media, working with a variety of D2C brands to maximize revenue opportunities. She specialized in multi-channel D2C programs that combined both traditional and emerging media channels to generate positive results through data driven analysis. Colleen has the unique ability to talk strategy in lay terms to guide teams in new and profitable directions, while building relationships based on trust and confidence. Prior to Bluewater Media, Colleen was the VP Account Director at D2C agency Acquirgy.

 

BioDerm promoted Alicia Lance to Sr. Director of Compliance for BioDerm and all affiliates. Alicia started at BioDerm in 2013, as a Manager of AMDI and most recently served as the Director of Customer Care and AMDI. She has built a strong customer care program at BioDerm based on integrity and dedication to patient outcomes. Alicia serves on the Medical Supply committee for AAHomecare and has over 20 years’ experience working in DME operations and compliance. She is excited to direct and expand BioDerm’s compliance program to enhance the company’s growth. Prior to BioDerm, Alicia worked at CCS Medical as a Compliance Manager. She holds a BS in Allied Health from the University of West Alabama.

 

About BioDerm

 

Headquartered in Largo, Florida, BioDerm is a leading provider of disposable medical devices and wound care supplies to patients with chronic conditions. BioDerm manufactures proprietary hydrocolloid products for urinary management, securement, infection control and skin protection, challenging accepted inferior standards of care by creating products that reduce infection rates, add comfort and reliability, and vastly improve quality of life. BioDerm’s flagship products for male urinary incontinence are Men’s Liberty for the home setting and Men’s Liberty Acute for in-patient settings. Other products include CathGrip for securement and BioPlus and FreeDerm for skin protection.

 

Wound Care Resources (“WCR”), a subsidiary of BioDerm, provides infection control products and other wound management supplies to patients with ventricular assist devices (VADs) installed due to heart failure, as well as other conditions.

 

For more information on BioDerm’s line of products visit www.bioderminc.com.

 

Contacts
Amy Stephens
Director of Marketing
727-416-2684

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005217/en/

It is not clear what methods Dr Yusuf Maraşlı uses to reduce amputations, this might be worth a watch anyway:

This includes the analogous nature of articular cartilage, muscle fascia, and intervertebral disc confirmed by way of comparative Scanning Electron Microscope analysis

PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ — Regenative Labs, a leading HCT/P manufacturer, has co-authored a pioneering paper together with experts from The Institute of Regenative Medicine and the Department of Pharmacology and Chemical Biology, Baylor College of Medicine.

 

“This paper is a market disruptor and will be our most significant paper released to date. This is the first literature that we are aware of to utilize Scanning Electron Microscope (SEM) images of actual tissue samples to objectively demonstrate on a qualitative and quantitative basis that collagen structural tissue matrices in our post-processed Wharton’s Jelly allografts and those in articular cartilage, muscle fascia, and intervertebral discs are analogous,” said Regenative Labs CEO, Tyler Barrett.

 

This research highlights our commitment to the Regenerative Medicine community. We believe the combination of our IRB-approved observational studies, peer-reviewed publications, ISO-certified laboratory processes, and our commitment to compliance with FDA and American Association of Tissue Banks (AATB) standards, sets the standard for HCT/P manufacturers. Regenative Labs has pioneered the use of perinatal tissue allografts and is pleased that this paper supports our current homologous use practices, consistent with our 361 status.

 

Currently, the treatments for the Intervertebral Disc (DDD) range in cost and effectiveness from an $8 bottle of Ibuprofen to $150,000 for spinal fusion (1). Neither of these treatment options target the foundational issue of ECM cartilage breakdown in the intervertebral discs. By age 35, 30% of people show signs of DDD; by age 60, this increases to 90% (2). That we are aware of, this is the first perinatal tissue allograft in the medical marketplace that may be applied in a homologous fashion per FDA 361 guidelines to replace or supplement missing or damaged connective tissue. All other non-surgical paradigms focus on symptom management and do not address the disc’s collagen structural degeneration. In collaboration with medical providers across the country, we are actively investigating additional homologous use applications for this technology in tissue defects associated with the load-bearing joints of the knee, hip, shoulder, spine, ankle, and foot.

 

Billions of dollars are spent annually on the surgical care and treatment of patients suffering from degeneration of load-bearing joints and intravertebral discs. We are honored to offer patients evidence-based and structural tissue defect-specific non-surgical applications on a global scale.

 

Additional Sources:

1. How much does degenerative disc treatment cost? CostHelper. (n.d.). Retrieved August 10, 2022, from https://health.costhelper.com/degenerative-disc.html
2. Degenerative disc disease. Columbia Neurosurgery in New York City. (2021, July 21). Retrieved August 10, 2022, from https://www.neurosurgery.columbia.edu/patient-care/conditions/degenerative-disc-disease

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs’s expert product research and development team complies FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

New Financing to Meet Significant Growth in Global Demand for MolecuLight’s i:X® and DX™ Point-of-Care Imaging Devices for the Wound Care Industry

 

TORONTO, Aug. 11, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has completed a financing with BDC Capital and iGan Ventures. The funds are to support MolecuLight’s continued global expansion to meet growing customer demand for its MolecuLight i:X® and DX™ devices. Leonard Kofman and Jody Staggs, Managing Director of SWK Holdings will join MolecuLight’s Board of Directors as observers.

 

“With the continued growth in global demand for our i:X and DX platforms, we are happy to announce this financing from BDC Capital and iGan Ventures, who has been an early investor in MolecuLight,” says Anil Amlani, CEO of MolecuLight Inc. “The proceeds will support the continued growth of our commercial operations and infrastructure to meet market demand”.

 

“We have invested in MolecuLight since inception and are thrilled to see the company achieve global commercial success,” says Sam Ifergan, Founder and President of iGan Partners. “Their customers continue to generate a wealth of published data showing the improved outcomes and cost savings, which is supporting MolecuLight becoming the standard-of-care in wound care globally”.

 

“BDC is proud to participate in the financing of MolecuLight, an impressive Canadian company that is making a global impact in terms of improving healthcare outcomes,” says Leonard Kofman, Partner with BDC Capital’s Intellectual Property-Backed Financing practice. “MolecuLight solved an unmet clinical need – the need to detect bacterial burden in wounds, and has commercialized a suite of products that is positively impacting wound care globally. Demand for the technology is strong and growing and we believe the company is well positioned for continued growth and success”.

 

The MolecuLight devices are sold in North America through its direct sales and clinical applications team and internationally through MolecuLight’s 15 specialized distributors in 18 countries.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which include two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

 

Tungsten Advisors served as the exclusive financial advisor to MolecuLight Inc.

 

About BDC Capital
BDC Capital is the investment arm of BDC, Canada’s bank for entrepreneurs. With over $3 billion under management, BDC Capital serves as a strategic partner to the country’s most innovative firms. It offers a full spectrum of capital, from seed investments to transition capital, supporting Canadian entrepreneurs who wish to scale their businesses into global champions. Visit bdc.ca/capital.

 

About iGan Partners:
Based in Toronto, iGan Partners is Canada’s leading health technology investors focused on disrupting the sector through breakthrough innovation that dramatically improve patent are while reducing costs. The firm focuses on identifying at an early-stage, then commercializing and scaling technological advancements in AI/Cloud-enhanced medical devices and digital health. iGan provides portfolio companies with smart-capital, active support, and access to a network of industry partners and sector-specific co-investors to help them grow and succeed.

 

About Tungsten Advisors:
Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and corporate finance for healthcare and technology companies. Tungsten provides transactional services including financings (private placements/PIPEs), corporate licensing and mergers and acquisitions (M&A). Tungsten also focuses on company incubation and makes direct investments alongside the creation of new companies in healthcare and technology.

 

Securities offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.

 

SOURCE MolecuLight

Future applications for the early, preventative use of amniotic membrane allografts in addition to the current standard of care for DFUs present a novel opportunity to reduce long-term morbidity and amputation risk in diabetic patients.

 

PENSACOLA, Fla., Aug. 8, 2022 /PRNewswire/ — A new MDPI study, co-authored by Regenative Labs signifies a huge win for patients suffering from diabetic foot ulcers (DFUs). DFUs are debilitating for an individual. They are painful, long lasting, and, even with proper care, can lead to amputation. The current standard of care for DFUs is debridement, the medical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. The increased healing time and augmented risk of amputation associated with the current standard of care only solidifies the need for new DFU treatment alternatives. Regenerative medicine is such an alternative.

 

With approximately 37.3 million diabetic adults in the United States, physicians are faced with an epidemic. Given the projected increase of 1.4 million new diagnoses of diabetes mellitus each year, advancing knowledge and care for the disease and its related conditions is especially relevant.

 

Regenative Labs’ AmnioText™, a dehydrated amniotic membrane allograft, was used to close a grade 5 wound according to the Curative Health Services (CHS wound grade scale), described as full thickness and subcutaneous tissues, exposed tendons, ligaments, and/or joints, plus necrotic tissue in the wound, in 7 weeks. Grade 5 wounds have a 91.5% rate of not healing at all. This unsettling outcome emphasizes the efficacy and importance of amniotic membrane allografts in revolutionizing the standard of care for DFUs.

 

The inability to heal DFUs presents a severe danger to patients as anywhere from 5 to 24% of untreated DFUs can lead to limb amputation within 6–18 months. These infections can lead to long-term impairment and possible lower-limb amputation without timely and correct management.

 

“Regenative Labs and our products are focused on ameliorating this problem with our outcomes-based approach. We provide the highest quality amniotic membrane allograft to allow doctors to provide predictable outcomes for their patients,” shared Regenative Labs CEO, Tyler Barrett.

 

Amniotic membrane allografts, such as those provided by Regenative Labs, have proven to augment the body’s ability to regenerate the structural tissue defects associated with DFUs; they are also comparable in cost to the standard of care, which averages about USD 17,245. Not only is the current standard of care for DFUs less effective, but it is also high in cost and typically relies on inpatient expenditures.

 

Medicare now recognizes the medical necessity of amniotic membrane allografts in the treatment of both DFUs and venous stasis ulcers. Consequently, many patients rely on Medicare to assist with the costs associated with DFU treatment. This presents the opportunity for human amniotic membrane allografts to be utilized in rural and underserved communities where DFU treatment is typically delayed due to high costs and a lack of supplies associated with traditional treatment. This could exponentially decrease the risk of amputations in diabetic patients in these rural and underserved communities.

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines.

 

Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

PENSACOLA, Fla., Aug. 1, 2022 /PRNewswire/ — Regenative Labs, a leading HCT/P manufacturer, and AAPC, the nation’s largest medical coding, training, and certification association, are pleased to announce a strategic healthcare compliance collaboration. By combining AAPC’s medical training and credentialing expertise with Regenative Labs’ human tissue allografts, together both organizations will support the pioneering of the first Wharton’s jelly allografts to be assigned a Q code and be approved for application directly to a defect using a syringe.

 

“This is an important step in furthering the mission of educating providers and elevating healthcare outcomes and we’re proud to be a part of it,” shared AAPC CEO, Bevan Erickson.

 

Regenative Labs received approval from the Centers for Medicare & Medicaid Services (CMS) to cover CoreText™ and ProText™, the first Wharton’s jelly allograft products recognized as a 361 HCT/P by CMS regulated under 21CFR 1271.10, establishing a new Level II HCPCS code Q4246 “CoreText or ProText, per cc.” According to CMS, both solutions provide the extracellular matrix needed for the infiltration, attachment, and proliferation of cells required to repair damaged tissue. They are typically used for muscle and cartilage tears and help repair damaged tissue due to wounds and tissue defects and are applied directly to the defect using a syringe.

 

Regenative Labs, now seeking to collaborate to further HCT/P compliance, recognizes the value AAPC brings to the healthcare industry as the world’s leading healthcare association, with more than 200,00 members and 30+ years of supporting healthcare professionals, providers, payers, and health systems

 

AAPC will deliver healthcare providers important coding resources, including full skeletal illustrations and applicable DX codes for Regenative Labs Wharton’s jelly allografts products for specialties, including Orthopedics, Pain Management, Podiatry, and Rheumatology. In addition, AAPC will create a customized web-based training module to ensure providers understand how to utilize more specific homologous applications with current DX codes to support accurate procedural reimbursement for these products.

 

“We look forward to the clarity this collaboration will bring to the market allowing proper documentation of homologous use applications,” said Regenative Labs CEO Tyler Barrett.

 

Regenative Labs firmly believes that no other organization understands coding regulations and documentation requirements better than AAPC, leading AAPC to be the right partner for this important project.

 

About AAPC: AAPC’s mission is to advance the business of healthcare by providing professional training, industry-standard certifications, and comprehensive solutions to individuals and organizations across medical coding, billing, auditing, compliance, and practice management. As the most trusted source for driving accuracy, profitability, and peace of mind, AAPC helps healthcare organizations reach the full potential of their revenue cycle. Learn more at AAPC’s website: www.aapc.com

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

 

This article was originally published here

Joins Cerner Code Program

WoundZoom Digital Wound Management solution now available in Cerner’s App Gallery

 

STEVENS POINT, WI – July 27, 2022 – Perceptive Solutions, Inc., developer of WoundZoom Digital Wound Management, today announced its integration partnership with Oracle Cerner and the availability of WoundZoom in the Cerner Code Program App Gallery. This partnership provides a secure and reliable exchange of wound care data between WoundZoom and a facility’s Cerner EHR system.

 

Perceptive Solutions joins the Cerner Code Program as a trusted integration partner so our customers can leverage the benefits of our validated application, WoundZoom, while eliminating additional steps in their workflow. Data captured using WoundZoom at the bedside, such as precise wound measurements, images, and clinical assessments automatically sync to patients’ charts, creating a more efficient workflow and a complete patient record in the EHR.

 

“Our innovative digital wound management solution enables clinicians to spend more time with patients through automated charting, wound imaging, and elimination of the manual measurement process. Cerner is a leading EHR provider for inpatient facilities and we are excited to provide accessibility of WoundZoom to Cerner customers,” said Mark Lacerte, President of Perceptive Solutions. “The technology integration through Cerner’s validation process enables a secure and reliable data flow from our solution into Cerner’s clinical charts. This enables healthcare facilities to more efficiently share valuable wound care data between both clinical and administrative team members within their EHR.”

 

About Perceptive Solutions

Perceptive Solutions modernizes the practice of wound care with technology-enabled systems designed to increase clinical efficiency, improve care quality, and mitigate risk. Integrating smoothly with your EHR, WoundZoom utilizes the latest AI and imaging technology to capture accurate wound images and measurements from your smart device, automatically prompt and document appropriate actions, and create a continuous, standardized clinical record across shifts, floors, and facilities. For more information, visit https://perceptivesol.com/.

 

Media Contact
Karen Guzdzial
Director of Marketing
(727) 225 7944
karen.guzdzial@woundzoom.com

Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

 

LEEDS, UK and TORONTO, July 13, 2022 /PRNewswire/ – MolecuLight Inc., the leader in fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced the publication of an independent, blinded randomized controlled trial in Diabetes Care. The publication on this 56-patient trial, titled “The use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial“1 reported that the use of a MolecuLight i:X® device to visualize the presence of elevated bacterial burden in wounds doubled 12-week wound healing rates (204%) in diabetic foot ulcer patients over standard-of-care alone.

 

Diabetes is a significant global health ailment: over 416 million people have diabetes worldwide2 and 25% of these patients develop a diabetic foot ulcer (DFU)3, greatly diminishing quality of life and increasing the need for costly and extended treatment. In the UK, the NHS spends £1 billion ($1.25 billion US) annually on DFU care and management24.

 

“As a clinician in wound care, especially when managing patients with chronic wounds, the holy grail is improvement in wound healing rates”, says David Russell, Associate Professor in Vascular Surgery at University of Leeds and lead author in the study. “In our randomized controlled trial, the results were impressive – the use of a MolecuLight device to inform our wound care decision-making helped us double the number of wounds that were healed at 12 weeks. This has benefits for the patient and our healthcare system.”

 

Patients were stratified into two groups, one in which the MolecuLight device was not used, and one in which clinicians used the MolecuLight device bi-weekly to assess diabetic foot ulcers for the presence of elevated bacterial burden. For the MolecuLight group, fluorescence imaging was performed after treatment. Fluorescence indicated the presence of elevated bacterial burden in over 80% of the wounds. Additional treatment based on imaging findings was performed as the discretion of the clinician, and most often included further debridement focused on the regions with elevated bacterial loads. Importantly, there was no increase in antibiotic prescribed in the MolecuLight group.

 

Alongside the impressive 2-fold improvement in healing rates, this study showed an association between baseline fluorescence and wound outcomes. Of the patients with negative fluorescence images at the baseline visit, 53.9% healed at 12-weeks, versus 37.5% with positive baseline fluorescence images. In other words, patients were 36% less likely to heal at 12 weeks if their wound was positive for high bacterial loads at the beginning of their treatment, as depicted by MolecuLight. Wound area reduction was superior in the MolecuLight arm and patient quality of life diverged toward improvement in the MolecuLight arm at 4 weeks and toward deterioration in the control arm at 12 weeks.

 

“To improve decision-making and care with DFU patients we must be able to measure what we manage. The MolecuLight i:X, as illustrated by the results in this RCT, is a powerful tool for screening DFUs for infection as well as monitoring new or worsening bacterial burden over time”, says David G. Armstrong, Professor of Surgery, Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine of the University of Southern California as well as the US-appointed delegate to the International Working Group on the Diabetic Foot (IWGDF). “This new study provides further data for the improved healing rates and improved patient care that can be achieved in a clinic with routine use of fluorescence imaging to detect wound bacteria.”

 

“We congratulate Dr. Russell and the team at Leeds for their excellent study and publication that shows the utility of MolecuLight to detect elevated bacterial burden and to inform clinical decision-making at the point-of-care”, says Anil Amlani, MolecuLight’s CEO. “A doubling of 12-week wound healing is a significant outcome and is consistent with what thousands of wound care clinicians are experiencing worldwide, that MolecuLight enables clinicians to deliver superior, proactive bacterial/infection management that improves wound outcomes”.

 

The Leeds Diabetes Limb Salvage service is now using the MolecuLight device to image all patients with wounds that are failing to achieve a healing trajectory within 4 weeks. To help manage patient volumes, patients who are negative with MolecuLight are triaged, and are then referred to community care as their wounds are considered manageable and able to achieve a healing trajectory.

 

This new RCT is part of a broad body of clinical evidence showing the many benefits of the MolecuLight i:X and DX devices across the range of wound care applications to help inform and improve clinical decision-making. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

1. Rahma S et al. Diabetes Care 2022;45(7):1601–1609
2. Diabetes UK: Diabetes Prevalence, www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019
3. Armstrong AG et al. The New England Journal of Medicine, 2017; 376:2367 – 75
4. Kerr, M, 2017, www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

For more information, contact:
Rob Sandler
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

The platform serves as a comprehensive resource for podiatry news and information to aid clinical decision-making and improve patient outcomes

 

MALVERN, Pa., July 12, 2022 /PRNewswire-PRWeb/ — As healthcare professionals across the podiatry community manage an ever-changing and complex field, HMP Global, the leading healthcare event and education company, today announced the launch of two value-added offerings, PodiatrySource and the Podiatry Learning Network.

 

The Podiatry Learning Network serves as the premier digital hub for podiatrists and offers direct access to clinically relevant news and information, expert perspectives, and continuing education. The network joins HMP Global’s portfolio of well-respected learning platforms dedicated to serving as online information hubs, and is a singular destination offering practical, relevant content and education guided by podiatry professionals.

 

Visitors to the new network can create a customized experience, selecting topic preferences most pertinent to them; receive regular e-mail updates with breaking news and carefully created content; grow professionally with the network’s repository of education; and connect with other podiatry colleagues around the world through the platform’s networking options.

 

“With the creation of the Podiatry Learning Network, HMP Global is delivering a single, definitive resource that podiatry professionals can rely upon to access important clinical knowledge on new therapies and treatments on a broad spectrum of topics, and enjoy a highly specialized content experience,” said David DePinho, President, HMP Global. “Healthcare professionals in the podiatry field will benefit from this comprehensive resource to receive ongoing professional development and provide the highest quality of patient care.”

 

PodiatrySource

 

HMP Global is also launching PodiatrySource, a one-stop resource with independent, clinically reviewed, and unbiased information to help clinicians make informed decisions about podiatry care products.

 

Powered by Podiatry Today, the award-winning, premier publication and online platform, PodiatrySource will reach buyers with the trusted information they need to act and make decisions about product selection and purchasing. It will provide 24/7 access to information on an interactive, user-friendly digital platform.

 

“The Podiatry Today audience is invested in providing patients optimal care and staying abreast of the latest product offerings across the field is part of how they achieve this goal,” said Jennifer Spector, DPM, FACFAS, Managing Editor of Podiatry Today, a trusted educational resource in podiatric medicine and surgery that provides engaging content to help clinicians improve patient care. “Creating PodiatrySource is a natural synergy of the education provided by Podiatry Today, with robust information about innovations provided by companies in the podiatric space.”

 

PodiatrySource currently highlights products focused on the office-based practitioner, and future updates will include more products and companies to best serve the full foot and ankle medical and surgical community, Spector said. PodiatrySource is open access with no subscription required for use. Industry contacts may submit product information through the website, and enhanced opportunities are available.

 

“PodiatrySource is designed to quickly become podiatry’s most relied upon tool to navigate the many options for products and services available to healthcare professionals in the podiatry community,” DePinho said. “It offers credible, trusted, non-biased clinically reviewed content that clinicians can use during the decision-making and purchasing processes.”

 

The new PodiatrySource resource guide is modeled after the highly successful WoundSource product reference guide. First published in 1998, WoundSource now includes more than 1,700 products manufactured by more than 200 wound care companies. Its digital companion, woundsource.com, includes product lists and reviews as well as articles, blogs by industry thought leaders, white papers, and other educational resources for wound care professionals.

 

For more information about PodiatrySource and the Podiatry Learning Network, visit hmpgloballearningnetwork.com/site/podiatrynet.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

 

Media Contact

Sandi Beason, APR, HMP Global, (601) 573-1737, pr@hmpglobal.com

 

SOURCE HMP Global

Wounds UK are pleased to announce the call for abstracts for the 2022 Wounds UK Annual Conference, held at the Harrogate Convention Centre, which will be held on 7-9 November 2022 at the Harrogate International Centre.

To submit your abstract use the following link: www.surveymonkey.co.uk/r/WUKH22Abstract

Poster presentations will be presented on electronic poster displays only, no hard copy posters will be on display.

Entries for the e-poster exhibition require you to submit an abstract. Every entry received will automatically be considered for the Wounds UK Award for Excellence 2022.

All abstracts will be reviewed by our judging panel, who will be looking to accept submissions that display high levels of innovation, relevance to current and/or best practice and provide high-quality research/evidence.

Award
The winner of the Wounds UK Award for Excellence will receive a free 3-day delegate pass with entrance to the gala dinner.

… read more

NANCY MORGAN

 

Every wound-care clinician treats diabetic patients regardless of your care point. In this course, Nancy will help you evaluate the wound, identify the best plan of treatment and steer you away from the potential setbacks for better healing rates and overall patient outcomes.

Objectives:

• Participant will identify the different types of Diabetes and Pre-diabetes and their effects on patients.
• Participant will identify skin conditions prone to patients with Diabetes.
• Participant will learn treatment options for Diabetic Foot Ulcers (DFU).
• Participant will discuss the high incidence of infections on patients with Diabetes and the importance of prevention.

… read more

Clinical and operational innovations better predict non-healing wounds and missed appointments

 

Further expanding its analytics capabilities and leadership position within the wound care marketplace, Net Health, a provider of specialty electronic health systems and advanced healthcare analytics, today announced the addition of two new predictive analytics resources to improve clinical and operational outcomes for wound care providers … The new Pressure Injury Deterioration Risk Indicator is built into Tissue Analytics, Net Health’s AI-powered wound imaging and analysis solution, which was recently granted breakthrough device status by the Food and Drug Administration (FDA). The Missed Visit Prediction Indicator is available in Net Health® Wound Care, one of the nation’s most widely used electronic health record (EHR) platforms for wound care. Both features are embedded in automated workflow processes and alert providers when risk is detected, enabling providers to intervene in real-time … read more

The Off-Loading Devices Market is expected to grow manifold in the upcoming period. With technological advancements like ML and AI being incorporated in abundance, the healthcare vertical is likely to reach the top pedestal in the years to come. There are Bluetooth-operated health monitors, which let doctors receive precise information, that too, from time to time … The unloading device is used to reduce physical stress on the ulcerative callus of diabetic patients, which is caused by poor circulation, lack of sensation in the foot, foot deformity or trauma. … These devices are designed to eliminate abnormal pressure points and promote healing … read more

New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria … Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of the new data on XF-73 with Cardiff University in Frontiers in Cellular and Infection Microbiology a peer-reviewed publication … read more

Regenative Labs CEO predicts this will have significant implications to advance multiple fields.

 

PENSACOLA, Fla., July 8, 2022 /PRNewswire/ — Regenative Labs, a leading FDA-registered and HTC/P manufacturer, confirms that the Institutional Review Board (IRB) of the Institute of Regenerative and Cellular Medicine (IRCM), an independent body which facilitates and validates regenerative and cellular medicine through collaborative and translational research, has approved its protocol for observational data of homologous use applications for Regenative’s products.

 

In noting receipt of the IRCM IRB letter, CEO Tyler Barrett observed that this is a key step in facilitating other studies for use of Regenative’s products. “We believe this will allow clinicians to explore new homologous use applications and make it easy to follow their patient outcomes,” he said, adding, “We are committed to advancing this field of research.”

 

The IRB letter confirms a key classification, known as 361, allowing Regenative to further studies for the use of its products.

 

“We are excited that this will allow us and our partner physicians to look for new uses,” said Barrett, pointing out that connective tissue is found throughout the body and that while the current use is heavily concentrated in addressing defects in the knee and specialties like orthopedics, Regenative has received queries and reports from specialties like podiatry and urology for cases of wound care and urinary incontinence.

 

In confirming receipt of the IRB’s letter, Regenative Labs confirmed their continued adherence to applicable state, local and federal regulations and requirements. They also look forward to a strong relationship with regulators.

 

The specific observational data collection approved is through MedngineTM of homologous use applications using ProTextTM, CryoTextTM,SecreTextTM, CoreTextTM and AmnioText.

 

Protocol number: RL-ME-002

 

IRB approval number: IRCM-2022-311

 

About Regenative Labs : Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at: https://regenativelabs.com.

 

SOURCE Regenative Labs

This article was originally published here

ActiGraft is an FDA-cleared wound care solution that enables health care providers to produce—in real time—in vitro blood clots from a patient’s whole blood. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes that naturally occur in the body. Testimonial: “I endorse ActiGraft as it uses the body’s own healing cascade to help initiate the wound healing process and has a unique role as a topical dressing in the wound care space.” —Dr. Bryan Doner, DO, D&P Medical Group … read more

Sarah Gardner and Sweta Rai

 

This session will help you understand the diversity and complexity of leg ulcers and also the management of unusual causes of leg ulcers. She aims to expand your knowledge base on different presentations of leg ulcers and will talk about evidence based management and newer techniques of leg ulcer management.

Dr Rai has an interactive and inclusive style of speaking and therefore questions and discussion will be very welcome during and after her talk … read more

Vegan diets have gained a lot of popularity around the world, mostly in America. About 6% of Americans claim that they are vegans. That is a 600% increase in veganism from 2017 to 2021. There are many reasons that people nowadays are adopting a vegan diet and it includes health and ethical reasons. One of the health reasons that this review refers to is type 2 diabetes. There have been previous studies of what a vegan diet has on the health and the prevention of metabolic syndrome. There have been studies that showed that the risk of cancer can be reduced on a vegan diet, but is still under debate that this is the main reason for it. The review aimed to show studies between vegan diets and see if there is a reduction in risk for type 2 diabetes … read more

Biofilm: A complex microbial community containing bacteria and fungi. The microorganisms synthesize and secrete a protective matrix that attaches the biofilm firmly to a living or non-living surface. The biofilm contributes to underlying wound infection, chronic inflammation, and delay in healing, and it is present in 80% to 90% of chronic wounds and 6% of acute wounds.

Epibole: Rolled or curled-under closed wound edges. These rolled edges are thickened epidermis that may be callused, dry, scaly, and/or hyperkeratotic. When epibole is present in a wound, it signals to the body that the wound has healed, even though the wound remains open. Epibole must be resolved to allow the wound to close … read more

Jennifer Spector, DPM, FACFAS

 

Each year, Podiatry Today hears from leaders in the world of foot and ankle medicine and surgery about important developments and significant strides being made in the field. Here is this year’s slate of the Top 10 Innovations in Podiatry (in no particular order) that could have an impact on your patients and practice … Pedilay med (Pedilay Care) is a ready-to-use secondary foot bandage that supports foot and ankle dressings associated with multiple conditions. The company explains that the bandage could save precious care time, as one can take it on and off in a swift and gentle fashion. The bandage, made up of a biocompatible, low-friction fleece material, has thin seams and can help protect the skin … read more

In a recent article published by GHP (Global Health & Pharma), Kent Imaging presents SnapshotNIR, their portable and lightweight near-infrared imaging device that is replacing some outdated and cumbersome technologies of the past, pioneering the future of effective wound care solutions. Through case studies and customer stories, clinicians share their hands-on experience with SnapshotNIR and how they are providing a greater standard of care to patients with this innovative technology … read more

FEATURED PRESENTERS: Mark Portou and Amelia Swift

 

What makes a wound complicated? Any non-healing wound can be described as complicated, but some are more complicated than others! Complicated wounds are usually found on patients with complex medical problems. Often complicated wound aetiology is multifactorial, but outcomes are significantly worse with underlying vascular disease. Medical optimisation and risk factor modification is required to treat the rest of the individual too … read more

TORONTO, July 7, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has been selected for a “Top Innovation in Wound Care 2022″ Award from Wound Management & Prevention (WMP) Journal for its MolecuLightDX™ device.

 

WMP provides news and information for professionals in wound care, ostomy care, incontinence care, and related skin and nutritional issues, and features ground-breaking research, peer-reviewed articles, and clinical discussions on topics relevant to the field. WMP and the Wound Care Learning Network are published by HMP Global, an omnichannel leader in healthcare content, events, and education.

 

MolecuLightDX was selected as a winner this year for its novel utility to provide a point-of-care tool to clinicians worldwide that enables the detection of elevated bacterial burden in wounds. Based on its extensive body of evidence and interviews with clinicians using it, the MolecuLight device is changing the standard of care in wound care.

 

“Wound Management & Prevention is dedicated to featuring the top innovations in wound care,” said Christiane Odyniec, Managing Editor. “Each July, the WMP Editorial Board nominates the newest innovations in the field of wound care, with the goal of sharing information to improve patient care. MolecuLightDX was nominated by our board for its innovation and practical applications, and we are pleased to recognize MolecuLight Inc. in this way.”

 

As part of WoundCon Summer 2022’s Technology Innovation Theatre, WMP will be hosting a webinar on “Wound Management & Prevention’s Top Innovations in Products & Care of 2022” on Thursday, July 14th at 1:30 PM EST. Five of the winning products will be featured, including the MolecuLightDX.
In this webinar, Dr. Charles A. Andersen, Medical Director of the Wound Care Clinic and Limb Salvage Program at Madigan Army Medical Center in Tacoma, WA will be speaking on his experience with MolecuLight and how it is changing his clinical practice. “Using MolecuLight has revolutionized our wound care practice and now allows us to provide proactive wound care,” says Dr. Andersen. “It’s a game-changer.”

 

Registration for the webinar is accessible here.

 

The MolecuLight i:X and DX devices are supported by a broad body of clinical evidence showing how they help to inform and improve clinical decision-making in wound care. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

• Image (Badge for a “Top Innovation in Wound Care 2022” Award from Wound Management & Prevention (WMP) Journal): Download
• Image (MolecuLightDX point-of-care device for imaging elevated bacterial loads in wounds and for performing stickerless digital wound measurement): Download  

 

SOURCE MolecuLight

Christopher Barrett, DPM, Dot Weir, RN, CWON, CWS

 

Provided by HMP Education, an HMP Global Company.

 

For questions regarding this educational activity, please call 609-371-1137 or email accreditation@hmpglobal.com.

 

INTENDED LEARNERS
This activity is designed for physicians, nurses, nurse practitioners, physician assistants and podiatrists across all practice settings involved in the prevention, treatment, and management of patients with wounds.

 

LEARNING OBJECTIVES
After participating in this activity, learners should be better able to:

Examine the efficacy and usability of disposable mechanically powered negative pressure wound therapy
Review best practices for using dNPWT in a variety of wound types
Explore illustrative case studies using dNPWT in a variety of wound types

… read more

Robert G Smith, DPM, MSc, RPh, CPRS

 

This Week’s Topic: Diabetic Foot Ulcer in Complex Patient

This week’s 5MinClinChallenge contributed by Robert G. Smith DPM MSc RPh FNAP, focuses on a complex diabetic ulcer patient involving alcohol and nicotine abuse, complaining of painful neuropathy. See if you agree with Dr Smith’s approach to this difficult case … read more

Terry Treadwell

 

This past weekend I was invited to be part of a group of wound care practitioners from the United States, Europe, Australia, and South Africa to design a manuscript to assist health care practitioners from around the world treat hard-to-heal wounds. At the meeting, cases were presented, and treatments were discussed, and it dawned on me that everything we were discussing was information that had been discussed many times before. It seems that no matter where in the world one treats wounds, the problems are the same and solving old problems is a major issue. As one who has had the privilege to teach and write about wound treatment in Sub-Saharan Africa, for me, the old topics became new again … read more

… read more

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) — About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and oversight of regenerative medicine products. The goal was to make sure these therapies – which are growing rapidly in numbers – are safe and effective for consumers, while also providing a framework to encourage innovation … The changing regulatory landscape provided the impetus for Merakris Therapeutics to immediately engage with the FDA on its technology and the steps required to meet the new requirements, according to the Research-Triangle headquartered company’s CEO, Chris Broderick. Merakris was one of the first companies in its industry to do so … read more

Medtech innovation briefing [MIB296]Published: 10 May 2022

The technology described in this briefing is Granulox … Granulox is a topical sterile haemoglobin spray for managing chronic non-healing wounds … The innovative aspects are that, unlike other oxygen delivery technologies, it is designed to allow oxygen to diffuse through wound exudate … It can also be used in various settings without costly consumables, electrical power or full or partial body coverage in a chamber … The intended place in therapy would be alongside standard care for people with chronic non-healing wounds … The main points from the evidence summarised in this briefing are from 8 studies (1 meta-analysis, 2 randomised controlled trials and 5 observational studies) including a total of 530 people … Seven studies were based in the UK and are generalisable to the NHS … The evidence suggests that Granulox may improve the management of chronic non-healing wounds … Key uncertainties around the evidence are that sample sizes are small, and most studies were not randomised and had a short follow-up period … read more

to Identify Regions Containing Elevated Load and More Bacterial Species

 

New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect
Clinically Significant Bacteria that Impedes Wound Healing

 

TORONTO, June 29, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion to its FDA 510(k) clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads (>104 CFU/g) in wounds. The expanded labelling also includes the device’s ability to identify areas of wounds containing more bacterial species, including key target pathogens of interest to the CDC that are major causes of antimicrobial resistance1. Detectable species include gram-negative and gram-positive species, aerobes and anaerobes. This expanded labeling is based on a detailed retrospective statistical analysis of over 350 patients.

 

 

“We are thrilled with the FDA’s new clearance for MolecuLight’ ability to determine the location of elevated bacterial loads in wounds, in addition to the ability to identify regions with more bacterial species of interest”, says Anil Amlani, MolecuLight’s CEO. “Clinicians worldwide are using the MolecuLight device to visualize regions with clinically significant bacterial loads and more species of concern. With point-of-care information on bacterial load and its locations through use of a MolecuLight device, clinicians can act immediately to tailor their cleaning, debridement, antimicrobial strategies and treatments accordingly.”

 

This video (courtesy of Rose Raizman) illustrates the importance of visualizing the location of elevated bacterial load in a wound. In this scenario, the clinician is using MolecuLight i:X to inform their decision-making and target their wound hygiene to the areas of red fluorescence. Regions of red, indicating that the wound contains clinically significant (>104 CFU/g) levels of bacterial burden, are clearly visible on the patient’s diabetic foot ulcer (see image).

 

In addition, the FDA has also recognized MolecuLight’s ability to visualize regions containing troublesome bacterial species at the point-of-care. The MolecuLight device can be used to enable fluorescence-guided tissue biopsies to these regions to detect a higher number of pathogens of interest (defined by the CDC as increasing risk to develop antibiotic resistance) compared to standard-of-care-guided biopsies. The CDC has identified antibiotic resistance as “one of the greatest global public health challenges of our time”1. Strategies to combat antibiotic resistance include containing emerging threats through early detection and aggressive response and improving appropriate antibiotic use through antimicrobial stewardship programs. The expanded use of diagnostic tools, like MolecuLight, to improve accuracy and speed of pathogen detection has been called out to help improve appropriate antibiotic selection and reduce unnecessary antibiotic use1.

 

MolecuLight was the first to receive FDA de novo clearance for its MolecuLight i:X imaging platform and has subsequently received three additional FDA 510(k) clearances for the device.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

www.moleculight.com

 

Image: Download at: https://moleculight.box.com/s/ax8758gz0f8amouhcjjvs4xzkfa9vofo
Video: https://youtu.be/HKOCGBlIQj4

 

SOURCE MolecuLight

 

 

In a study of over 7,000 chronic limb-threatening ischaemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention rates; survival, however, was higher among Black patients and similar between Hispanic and White patients. Aderike Anjorin (Duke University Medical Center, Durham, USA) delivered these findings at this year’s Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2022; 15–18 June, Boston, USA) … Framing the research, Anjorin stated that Black and Hispanic patients have higher rates of CLTI and suffer worse outcomes after lower extremity bypass compared with White patients. The underlying reasons for these disparities are unclear, she said, specifying that data on long-term outcomes are limited. In order to address this gap in the literature, Anjorin and colleagues examined differences in three-year outcomes after open infrainguinal … read more

MEMPHIS, Tenn.–(BUSINESS WIRE)–FedEx Corp. (NYSE: FDX) and Direct Relief continue to support those affected by the conflict in Ukraine. On Sunday, June 26, FedEx Express safely delivered 52 tons of critical medical aid to Poland from the United States via a FedEx humanitarian relief flight. This follows FedEx and Direct Relief’s first charter flight of aid for Ukrainian refugees in March and is the latest in a continuous series of shipments from Direct Relief … Aid aboard the FedEx Express Boeing 777 cargo aircraft included substantial quantities of emergency medicines and supplies, including health kits, trauma and wound care items, chronic disease and chemical exposure medications, and antibiotics. All items were provided at the request of, and approved by, Ukraine’s Ministry of Health and local Ukrainian organizations. Direct Relief team members were on site for the offload and the aid will be distributed to health facilities within Ukraine … read more

Hayley Ryan and Helen Jentz

 

Wounds Australia celebrated its 28th anniversary this year. Like many peak national organisations, over the course of our history, Wounds Australia has had to evolve and adapt to the ever-changing health and social landscapes in which we operate. Central to our ongoing success as a peak body is the commitment of our members, the health professionals who have chosen to dedicate themselves to the highly specialised and complex area of wound prevention, diagnosis, treatment, care, healing and research … As an organisation that is focussed on effective, real and sustainable systemic change that will result in significant improvements in the lives of Australians living with wounds, we are also dedicated to broadening the ways in which we, as the peak national body for wound prevention, treatment and healing, can support and assist those living with wounds and the families who love and care for them … read more

Allyson Y. Schwartz, Jon Bloom, M.D.

 

Lower limb amputations are devastating for people living with diabetes, particularly for Black Americans facing poor access to comprehensive care. A coordinated, data-driven national prevention strategy is the only way to curb this growing epidemic for all at-risk populations … When President Joe Biden rightly called out the unsustainably high price of insulin in his 2022 State of the Union Address, he wasn’t saying anything new for most industry observers. Rising insulin prices have been the subject of national conversation for years, and the push for a reasonable cap on out-of-pocket expenses has been a perennial rallying point among providers and patient advocates … Capping insulin costs is an important step, but it is just a start if we are going to stop people living with early diabetes from experiencing a worsening of their condition … The statistics and the people behind those numbers demand greater attention, smarter care, and a life free of the serious consequences of uncontrolled, complex diabetes … Consider these numbers. More than 37 million people are living with diabetes in the United States — and a further 96 million individuals have prediabetes … read more

Hemostatic Solutions for Trauma Injuries Presents Opportunities – ResearchAndMarkets.com

The “Growth Opportunities in Military Medical Device Technologies” report has been added to ResearchAndMarkets.com’s offering … Over the years, the healthcare industry has developed several unique technologies for emergency medical services and critical care. An important user of critical care healthcare products is the military or the defense forces. Advanced medical technologies have improved the care that is offered, and they also enable safer and quicker care for soldiers … Severe hemorrhages can result in hemodynamic instability, hypoxemia, multiple organ failure, or death. A key reason for patient fatality is blood loss due to trauma or injury on the battlefield. Typically, intravenous (systemic) or local (topical) hemostatic agents are used to control excessive bleeding … read more

Eli Cahan

 

Leafer Miller didn’t hear much after the doctor told him they had to “sacrifice the leg.” … Lying on the emergency room gurney, the self-proclaimed video game nerd and former athlete struggled to comprehend life without the leg that had propelled him on the track and to the turf for tackles on the soccer field … “It was always in the back of my mind as a worst-case scenario,” the 35-year-old Fresno, CA, native says. “But I wasn’t expecting that to be the case.”
… read more

Robin Lenz and Fahad Hussain

 

For the patient, the prevention of sores and injuries is better than treating them. Pressure-relieving mattresses may be essential for preventing pressure injuries (bed sores). These mattresses aid in relieving and redistributing pressure and can thereby cause a reduction of friction and shearing. Pressure-relieving mattresses provide support for the body and reduce the amount of force applied to a given area. Thus, for bedbound patients and patients who are unable to reposition themselves, these types of beds can be especially beneficial … read more

We (The Society of Tissue Viability) have over 100 resources, free for everyone to browse and read and share. These resources are suitable for a range of skin and wound care disciplines, roles, and educational purposes.

 

The university-level modules are aimed at supporting Continuing Professional Development and cover a range of topics from basic skin anatomy and physiology through to wound healing and dressing selection.

 

The five higher tier modules are fully endorsed by the Society of Tissue Viability.

 

You will need to sign up to the ActivHeal Academy to access these courses

 

Module 1: Anatomy & physiology of the skin
To understand how wounds heal, it is important to have a basic knowledge of the anatomy and physiology of the skin and the structures that lie within it. ESTIMATED TIME REQUIRED: 60 MINUTES

 

Module 2: Wound healing
After an injury to the body has occurred, healing of the wound takes place in order to restore the intact barrier provided by the skin. ESTIMATED TIME REQUIRED: 60 MINUTES

 

Module 3: Patient and wound assessment
This module looks at the important criteria to consider including wound assessment tools to encourage you to critically analyse established wound assessment tools used within the clinical environment. ESTIMATED TIME REQUIRED: 90 MINUTES

 

Module 4: Wound classification and wound management
This module will look at different wound types and the most frequently used methods by which they are staged and managed. This is meant as a guide and may compel you to look at the research behind your current practice.

 

Module 5: Dressing selection
As the number of wound care dressings available on the market continues to grow this course looks to ensure that the correct treatment is carried out. ESTIMATED TIME REQUIRED: 90 MINUTES

 

https://academy.activheal.com/

Special Report on MASD written by Elizabeth Faust, MSN, CRNP, CSWS, CWOCN-AP, MAPWCA; Siobhan McCoulough, CNS; and Patricia Idensohn, CNS

 

Moisture-associated Skin Damage (MASD), as the name suggests, occurs when exposure to a moisture source results in a breakdown of skin integrity. MASD is an umbrella term for a number of conditions including incontinence-associated dermatitis, peri-stomal skin damage, peri-wound skin damage and intertrigo. These conditions can impact greatly on patients so protecting the skin from damage and promoting wound healing are integral parts of skin and wound care. This area contains a variety of different resources to help aid understanding of MASD, so please sign up to our events, and explore to learn more!
… read more

Oleg Teleten, MS, RN, CWCN
Tatyana S. Polyak, MD
Jessica Espinoza, OTS
Andrew I. Li
Ariel J. Rodgers, MD
Holly Kirkland-Kyhn, PhD, FNP, GNP, CWCN, FAANP

 

Pressure ulcers/injuries (PU/Is) are still highly prevalent in the acute care setting. According to the Joint Commission Center for Transforming Healthcare (2021), more than 2.5 million patients in US acute care facilities are estimated to have PU/Is each year, and 60,000 die of their associated complications.1 PU/I development has many contributing factors, including prolonged pressure over bony prominence due to inactivity/immobility, shearing between skin surface and mattress/seating surface,2 poor perfusion,3 tissue ischemia, and prolonged high surface interface pressure.4-6 Incidence of PU/Is has been shown to be associated with increased disease burden, financial burden, and increased in-hospital mortality rates … read more

… read more

In this video, Paul Kim, DPM, MS, FACFAS, discusses the clinical implications and considerations of using negative pressure wound therapy with instillation in wound care.

Paul Kim, DPM, MS, FACFAS, is a professor in the Department of Plastic Surgery and Orthopedic Surgery and is the Medical Director of the Wound Program at the University of Texas Southwestern in Dallas, Texas. For more content, visit the Negative Pressure Wound Therapy topic center … watch video

This table illustrates common wound care services and procedures performed at hospital outpatient settings, and refers to Centers for Medicare & Medicaid Services (CMS) facility fees. For Medicare Physician Fee Schedule, see topic “HCPCS/CPT Codes Commonly Utilized in Wound Care and HBOT”.

Instructions for the interactive Tool below: 1. Select number of entries (rows) to be displayed on the table. 2. Use the “Search” field to find a specific code or description. For educational purposes only. Your hospital chargemaster, Medicare Administrative Contractor (MAC) and Coverage Determinations should serve as the definite source of billing guidelines … read more

Patients with systemic sclerosis who demonstrate digital ulcers use “significantly more” health care resources annually than patients without digital ulcers, according to data published in Arthritis Care and Research … “[Digital ulcers (DUs)] are slow to heal, specially if there is calcinosis, and can be complicated by soft tissue infections, wet and dry necrosis, eschar, underlying tissue exposure, gangrene, osteomyelitis, and amputation,” Tatiana Nevskaya, MD, PhD, of the Schulich School of Medicine and Dentistry, in Ontario, and colleagues wrote … read more

By signing up to LeaRn On Demand today you will have access to:

• E-learning modules covering wound care, compression therapy and much more, that can contribute to the non-participatory hours of CPD required for revalidation
• L&R brand videos, resources and information
• A new community where you can connect with others in your profession
• A platform to ask questions at any time!

… read more

Many people have now embraced the plant-based meat movement. Plants high in protein, such as soybeans, are common ingredients, but it’s been unclear how much of the nutrient makes it into human cells. In ACS’ Journal of Agricultural and Food Chemistry, researchers report that proteins in a model plant-based substitute were not as accessible to cells as those from meat. The team says this knowledge could eventually be used to develop more healthful products … read more

During (National) Diabetes Awareness Week from 13 to 19 June 2022, Neuropad® a 10-minute pain-free screening test for the early detection of diabetic foot syndrome, a condition which can lead to serious complications such as foot ulceration, and amputation is raising awareness about this condition. Foot complications are the most feared of all the complications of diabetes, however, alarmingly, 30% of people with diabetes are unaware that foot complications are common and serious if detected late. Another sobering statistic is that the five-year mortality post amputation is worse than most common cancers and much higher than breast cancer … Nerve damage to the feet is a common complication of diabetes, but often goes unnoticed. Neuropad helps solve this problem with a simple colour change test, that provides an early warning sign … read more

Chronic wounds affect nearly 15% of Medicare patients (8.2 million people) and may cost as much as $96.8 billion per year. The most common are not venous or diabetic, even though they are the most often studied in prospective trials. The most common chronic wounds are surgical incisions that dehisce and the “wounds with no name” due to the patients’ underlying medical conditions. That is because wounds are not a disease – they are a symptom. The US Wound Registry (USWR), a 501 (c)(3) non-profit organization, has been a patient registry since 2005. Since 2014, the USWR has been recognized by the Centers for Medicare and Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) that collects medical and/ or clinical data for the purpose of improving the quality of patient care. While we understand that randomized, controlled trials are needed to demonstrate efficacy in a perfect world, real-world patients have an average of 6 serious co-morbid conditions and take 10 medications. These complicated patients are invariably excluded from clinical research studies, which makes it impossible to know what treatments work best … read more

The agenda has not yet been confirmed for this meeting. Please check again at a later date for more information, or call on 020 3735 8244.
… read more

We have recently been informed by our long-term funder, the NIHR, that funding for all the review groups they currently fund will terminate on 31 March 2023, and at that point Cochrane Wounds will also cease to exist. This means that we have to make difficult decisions about which reviews we will support between now and then, as our resources are limited in amount and duration.

Unfortunately, we will not be able to accept new titles and we will only proceed with high priority, high quality reviews that meet deadlines and can be produced relatively independently by author teams in an efficient way … read more

Why Do Chronic Wounds Contain Biofilm?
The process of wound healing ideally progresses from inflammation to epithelialization and, finally, remodeling. If at any point bacterial (or fungal) colonization becomes prominent, the process of wound healing is disrupted. The creation of biofilm is a microbial defense mechanism that stalls the trajectory of healthy wound healing and can contribute to the development of a chronic wound. It is estimated that 90% of chronic wounds and 6% of acute wounds contain biofilms generated by microbes.1,2 Epidemiologically, chronic wounds impact 2% of the entire US population.2 Because of this large impact, knowledge of proper wound healing and use of clinical tools to assist the wound healing process are essential … read more

Keynote Speakers: Sarah Gardner, Kristina Stiles, Paul Hardy

 

Free service specific/specialist days promote the best practices in skin health and wound healing … Caring for children with a chronic illness or disability can pose many challenges to healthcare professionals. Frequently this includes the risks associated with maintaining skin integrity and wound healing when faced with complex factors that can impact on patient outcomes … This advanced study day will explore some of the factors that need to be considered when assessing children with complex skin and wound care needs and will also provide insight into managing specific conditions such as pilonidal sinus, pressure ulceration and leg ulceration … read more

Chronic and nonhealing wounds are a worldwide issue and are becoming more difficult to treat. In the United States alone, according to Medicare, over 8 million Americans have chronic wounds that cost the national health care system between $18.1 and $96.8 billion per year.1 If standard treatment does not adequately heal a wound, additional methods of wound care treatment may be required, and the underlying disorder must be examined to determine the need for advanced wound care modalities. Advanced wound care therapies are interventions that are used after standard wound care has failed … read more

Module 1: The Skin

 

This forms part of a series of modules you can access to develop your knowledge and understanding of wound care. This module is endorsed by The Society of Tissue Viability

 

By the end of this module, you will be able to:

• Name the different layers of the skin
• Recognise how the different layers interact with each other
• Recall the functions of the skin
• Recognise the effects of ageing on the skin
• Complete the 15 minute version of this module to download a training certificate which can go towards CPD revalidation: https://youtu.be/BcImfXNwwK4

 

This video is intended for health care professionals. It is offered for informational and educational purposes only and is not intended as medical advice. Viewer discretion is advised.

 

… read more

Validation study to assess up to 200 adult subjects with participation from leading U.S. principal investigators.

 

DALLAS, June 14, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the start of its clinical validation study to support the development of its Diabetic Foot Ulcer (“DFU”) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and Artificial Intelligence (AI) to provide clinicians with an immediate healing assessment for DFU, which enables clinicians to provide a more accurate and timely diagnosis for therapeutic intervention.

 

The study will collect data from up to 200 adult subjects across seven potential clinical sites to further develop DeepView®’s AI algorithm. Patient enrollment for the validation study began this month and is expected to complete in November 2022.

 

Building upon promising results from the clinical training study, where the current diagnostic accuracy is 81%, the data collected from the validation study will be used to bolster the Company’s existing clinical database of DFU images and physiologic information to train and improve the DeepView® AI algorithm. Additionally, the validation study will collect data from a broader population set of up to 200 subjects to increase geographic and ethnic variability. Importantly, data collected will support the Company as it prepares FDA and CE mark submissions for DeepView®’s DFU indication, planned in 2023.

 

Participating investigators include: Dr. Alisha Oropallo, MD, Director of Comprehensive Wound Healing Center at Northwell Health; Dr. Brock Liden, DPM, Podiatry Specialist at Circleville Foot & Ankle Center, LLC; and Dr. Babajide Ogunllana, DPM, West Houston Foot and Ankle Center. Additional clinical sites are being evaluated and will be incorporated into the validation study in the near future.

 

Dr. Alisha Oropallo, M.D., FACS, FSVS, Director of Comprehensive Wound Healing Center at Northwell Health and National Principal Investigator for the study, commented: “For patients with diabetes, foot ulcers can impact their quality of life and lead to complicated infections and potential amputation. I look forward to participating in this study as DeepView® has significant potential to improve the current standard of care, resulting in faster application of advanced therapy, better wound healing and reduced overall hospital visits and utilization.”

 

Mary Regan, Ph.D., VP of Clinical Affairs at Spectral MD, said: “We are very pleased to have initiated the Clinical Validation Study, the next critical step towards the completion of development for the DFU application for DeepView® Wound Imaging System. To obtain robust clinical data, the Spectral MD team has selected leading wound care providers to advance and develop our DeepView® Wound Imaging technology. I look forward to working with all participating clinical sites to ensure high-quality data and clinical engagement.”

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView®Wound Imaging System.

 

www.spectralmd.com

 

info@spectralmd.com

 

This article was originally published here

The Alliance submitted detailed comments and recommendations to Novitas on its Draft LCD on Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (DL35041) and accompanying draft Local Coverage Article (DA54117). In April oral comments submitted at Novitas’ public meeting, the Alliance had flagged – among other issues – provisions in the policy not supported by scientific evidence, as well as conficting and/or clinically incorrect policy language. In written comments, the Alliance submitted a chart (attachment A) detailing the specific provisions/policy language it flagged as problematic, the issues of concern underlying to those provisions, specific language changes to address the concern, and the clinical evidence supporting these recommendations. The chart was accompanied by additional attachments, including HCPCS and ICD-10 Codes to be added and a red-lined mark-up of suggested line edits (attachments B-E). See comments and attachments below … read more

Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces it will participate to the scientific symposium “Phage therapy: French experience”, which will be held on June 15, 2022 from 5:15 pm to 6:30 pm in the amphitheater A of the Palais des Congrès in Bordeaux, as part of the 23rd National Days of Infectiology (NDI).

 

The symposium, moderated by Dr. F.-A. Dauchy from the Bordeaux University Hospital, will host the following presentations:

 

Phagotherapy and IOA. Compassionate cases and clinical studies including PhagoDAIR: Pr. T. Ferry (Lyon)
Phage therapy and Infections of the Diabetic Foot Ulcer. State of knowledge. PhagoPied: Pr. A. Sotto (Nîmes)
Phage therapy and pulmonary infections. Preclinical results. Planned clinical studies: Dr. A. Bleibtreu (Paris)
Pascal Birman, Medical Director of Pherecydes Pharma, comments: “Antibiotic resistance is a major public health issue and is a central theme at this 23rd edition of the NDI. This symposium is an opportunity to highlight the interest of phage therapy through several clinical studies that will be conducted in different indications and through compassionate treatments already performed with our phages. Pherecydes Pharma and its partners are doing their utmost to ensure that these studies provide useful answers to improve the treatment of patients suffering from antibiotic resistant infections.”

 

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

 

For more information, www.pherecydes-pharma.com

 

Contacts
Pherecydes Pharma
Thibaut du Fayet
Deputy CEO
investors@pherecydes-pharma.com

 

NewCap
Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92

 

NewCap
Arthur Rouillé
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 00 15

 

This article was originally published here

Once a pressure injury has appeared, you need to take immediate action. Contact your health professional for all pressure injuries regardless of the stage. You may be referred to a wound care specialist to help heal your wound. Do not be embarrassed as you know pressure injuries develop for a variety of reasons, many of which do NOT include lack of care on your part. A pressure injury usually occurs due to combinations of reasons that can include self-care issues but also metabolic reasons … You need to be evaluated for treatment. If the wound is open, a treatment plan will be made for you to follow. If you see a change in pigmentation without an opening in the skin that you have dealt with previously, you may already know your plan. You will need to work with your healthcare professional if an area is repeating pressure injuries … read more

According to new research by investigators at the Mayo Clinic and Washington State University, e-bandages could be an effective alternative to antibiotics for managing wound infections. The findings are presented at ASM Microbe 2022, the annual meeting of the American Society for Microbiology … In a recent study conducted in mice, novel hydrogen peroxide producing bandages with electrical/chemical properties (electro-chemical bandages or e-bandages), under the control of wearable voltage devices, reduced methicillin-resistant Staphylococcus aureus (MRSA) biofilm bacteria present in the wound by 99 percent after 2 days of treatment … read more

13-Jun-2022 8:05 AM EDT, by Orpyx Medical Technologies Inc.

 

Newswise — CALGARY, AB, June 13, 2022 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services. This remote monitoring program drives engagement and extends mobility for people living with diabetes by transforming patient care through real-world patient data, analytics, and coaching.

“The launch of Orpyx SI Flex is our next step in enabling Diabetes Healthspan Extension™,” stated Dr. Breanne Everett, CEO and co-founder of Orpyx. “In North America, one-third of people are living with diabetes or pre-diabetes which often requires juggling an overwhelming number of actions, measurements, and appointments. By taking a holistic approach through a digital care platform we can dramatically improve upon the current standard of care. We are starting with foot care through robust data generation via our sensory insoles, and supporting patient engagement through RPM and coaching.”

 

The Orpyx SI Flex Sensory Insole system is a wearable technology designed to help prevent plantar foot complications for at-risk patients with peripheral neuropathy. “It is like having a supercomputer on the bottom of each foot,” said Denis Brisson, Chief Operating Officer at Orpyx. “Plantar pressure is a leading cause of foot ulceration so by measuring sustained high pressure we can help eliminate the root cause of many of these wounds before they happen.”

 

Along with pressure, the system captures wear time to determine how compliant the patient is to their provider’s treatment plan, step count to help dose activity levels, and temperature the last line of defense to indicate when inflammation is present and tissue damage is occurring. The ultra-thin, prefabricated sensory insoles fit in most every-day footwear, making them practical and comfortable for a broad range of patients.

 

Orpyx is changing the conversation by initially focusing on preventing foot ulceration by generating the most robust set of real-world plantar data. Historically, the focus has been on how to treat patients’ foot ulcers after they have already formed, with disappointing results as 25% of people with diabetes will develop an ulcer during their lifetime. These ulcers have a detrimental impact on patients’ mobility often resulting in life-shortening events such as amputation which can cause a ripple effect of social isolation, mental health challenges, and in the most complex situations death. Most diabetic foot ulcers (DFUs) are preventable, so we are on a mission to help patients and providers achieve improved, sustainable outcomes.

 

“Healthcare systems cannot sustain the current clinical strain of managing the 34 million people with diabetes in the US and the resulting $176B in financial costs. One third of this cost is attributed to lower limb care which is why this is such important work,” continued Dan Hughes, Orpyx’s Chief Commercial Officer. “Orpyx SI Flex Sensory Insoles and our new RPM services were specifically developed to meet these challenges head-on. Our insoles will play a significant role in the diabetic care pathway enabling patients to take proactive steps to manage their diabetes while reducing the total cost of care for Commercial Payers and Integrated Delivery Networks across the United States. Ultimately, this technology drives alignment and better outcomes for patients, providers, payers, and physicians.”

 

Healthcare providers seeking additional information to help their patients prevent DFUs can learn more about the new Orpyx SI Flex Sensory Insoles at https://www.orpyx.com/orpyx-si-flex-sensory-insoles.

 

About Orpyx Medical Technologies Inc.

 

Founded in 2010, Orpyx® Medical Technologies Inc. (“Orpyx”) is a Calgary-based digital health company. We take a holistic approach to remote “anywhere” care, which includes the company’s proprietary, imperceptible sensory insole platform that detects pressure, temperature, gait, activity, and movement symmetry. Our comprehensive Orpyx SI® Sensory Insole system enables continuity of care between visits to provide optimal remote care for people living with diabetes or recovering from surgery. The patient’s data is uploaded to the Orpyx SI cloud-based dashboard, where accredited healthcare practitioners remotely monitor it. The remote monitoring team communicates directly with the patient between care visits to ensure ongoing continuity and quality of care.

 

Visit www.orpyx.com for more information.